Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
25-Feb-2008
The test, known as CRS7, is the first clinical test capable of predicting the likelihood of an HCV patient's risk of progressing to liver fibrosis and cirrhosis. According to the company, the availability of this test will substantially aid in the clinical management of HCV patients by ensuring they receive accurate, personalised treatment. The test has been clinically validated through multi-centre studies in North America.
Most read news
Organizations
Celera Genomics
Applera
Lab21
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.